Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. VKTX
stocks logo

VKTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.903
+182.21%
--
--
-0.961
+134.45%
--
--
-0.999
+72.2%
Estimates Revision
The market is revising No Change the revenue expectations for Viking Therapeutics, Inc. (VKTX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 42.96%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+10.27%
In Past 3 Month
Stock Price
Go Up
up Image
+42.96%
In Past 3 Month
Wall Street analysts forecast VKTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VKTX is 97.27 USD with a low forecast of 70.00 USD and a high forecast of 125.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast VKTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VKTX is 97.27 USD with a low forecast of 70.00 USD and a high forecast of 125.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 38.570
sliders
Low
70.00
Averages
97.27
High
125.00
Current: 38.570
sliders
Low
70.00
Averages
97.27
High
125.00
Canaccord
initiated
$106
2025-10-29
Reason
Canaccord
Price Target
$106
2025-10-29
initiated
Reason
Canaccord initiated coverage of Viking Therapeutics with a Buy rating and $106 price target.
Canaccord
Edward Nash
initiated
$106
2025-10-29
Reason
Canaccord
Edward Nash
Price Target
$106
2025-10-29
initiated
Reason
Canaccord analyst Edward Nash initiated coverage of Viking Therapeutics with a Buy rating and $106 price target. The firm views Viking as a leader in the obesity drug development space. It expects a readout from the company's two Phase 3 trials in 2027 and mid-2028, respectively. Viking also reported "strong" efficacy Phase 2 data in August from the oral version of VK2735, the analyst tells investors in a research note. Canaccord believes the drug can differentiate on "multiple fronts."
JPMorgan
Overweight
downgrade
$80 -> $75
2025-10-24
Reason
JPMorgan
Price Target
$80 -> $75
2025-10-24
downgrade
Overweight
Reason
JPMorgan lowered the firm's price target on Viking Therapeutics to $75 from $80 and keeps an Overweight rating on the shares.
Morgan Stanley
Overweight
maintain
$98 -> $102
2025-10-23
Reason
Morgan Stanley
Price Target
$98 -> $102
2025-10-23
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on Viking Therapeutics to $102 from $98 and keeps an Overweight rating on the shares. The VANQUISH-1 obesity and VANQUISH-2 Type 2 diabetes plus obesity trials are enrolling ahead of schedule, notes the analyst, who also notes that management plans to meet with the FDA in an end-of-Phase 2 meeting for oral VK2735 in Q4 with a Phase 3 start targeted soon after. The firm is "encouraged by swift execution across programs," the analyst tells investors after the company's Q3 update.
Cantor Fitzgerald
Overweight
maintain
$105
2025-10-23
Reason
Cantor Fitzgerald
Price Target
$105
2025-10-23
maintain
Overweight
Reason
Cantor Fitzgerald tells investors after Viking Therapeutics' "transformative" Q3 update that "this was the most bullish update Viking has given since we started covering the stock more than 7 years ago." Viking "just crystallized five critically important data catalysts in the next 24 months" and the company affirmed cash on hand of greater than $700M was sufficient to get through all of them, according to the analyst, who has an Overweight rating and $105 price target on Viking shares.
B. Riley
B. Riley
Buy
maintain
$85
2025-08-20
Reason
B. Riley
B. Riley
Price Target
$85
2025-08-20
maintain
Buy
Reason
B. Riley views the selloff in shares of Viking Therapeutics following VK2735 oral weight loss data as overdone. The pullback indicates the dataset disappointed investor expectations, particularly as cross-trial comparisons are being made to Eli Lilly's (LLY) oral GLP1 orforglipron, the analyst tells investors in a research note. Riley's base case of oral VK2735 remaining important to the maintenance therapy phase is unchanged. It reiterates a Buy rating on Viking with an $85 price target. The stock closed Tuesday down 42% to $24.363.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Viking Therapeutics Inc (VKTX.O) is -9.89, compared to its 5-year average forward P/E of -17.54. For a more detailed relative valuation and DCF analysis to assess Viking Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-17.54
Current PE
-9.89
Overvalued PE
0.02
Undervalued PE
-35.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-12.20
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.51
Undervalued EV/EBITDA
-25.91

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
209.94
Current PS
0.00
Overvalued PS
796.67
Undervalued PS
-376.79
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 299.39% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 299.39% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

VKTX News & Events

Events Timeline

(ET)
2025-11-19
05:20:48
Viking Therapeutics finishes enrolling patients for the VANQUISH-1 clinical trial.
select
2025-11-06 (ET)
2025-11-06
07:55:19
Viking Therapeutics' VK2735 Obesity Program Demonstrates Effectiveness in Recent Findings
select
2025-10-22 (ET)
2025-10-22
16:22:34
Viking Therapeutics Announces Q3 Earnings Per Share of 81 Cents, Exceeding Consensus Estimate of 67 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
03:57 AMBenzinga
What’s Behind the Surge in Viking Therapeutics Stock?

  • Viking Therapeutics Stock Performance: Viking Therapeutics Inc (VKTX) shares are experiencing a significant rise, trading 11.17% higher at $35.29, driven by positive developments in the obesity treatment sector and successful patient enrollment in its Phase 3 clinical trial for VK2735.

  • Market Context and Competition: The broader obesity drug market is gaining momentum, with major players like Eli Lilly and Novo Nordisk competing fiercely, prompting increased investor interest in emerging companies like Viking Therapeutics.

  • Technical Analysis: VKTX shows strong short-term momentum, trading above key moving averages, but its longer-term performance indicates volatility, with a 12-month decline of 23.61%, highlighting the need for careful monitoring.

  • Investor Engagement: Viking is participating in the Piper Sandler 37th Annual Healthcare Conference, where executives are expected to discuss recent clinical developments, further engaging investors in the company's progress.

[object Object]
Preview
8.0
02:00 AMNASDAQ.COM
Significant Options Activity on Thursday: GM, VKTX, LUNR

  • Viking Therapeutics Options Activity: Viking Therapeutics Inc (VKTX) experienced significant options trading with 29,557 contracts, equating to about 3.0 million underlying shares, primarily driven by the $50 strike call option expiring January 16, 2026.

  • Intuitive Machines Options Activity: Intuitive Machines Inc (LUNR) saw a high options trading volume of 46,961 contracts, representing approximately 4.7 million underlying shares, largely influenced by the $12 strike call option expiring December 19, 2025.

  • Trading Volume Comparison: The options trading volumes for VKTX and LUNR accounted for approximately 84% and 78.1% of their respective average daily trading volumes over the past month.

  • Further Information: For additional details on available expirations for GM, VKTX, or LUNR options, StockOptionsChannel.com can be visited.

[object Object]
Preview
9.5
11-27NASDAQ.COM
Regeneron (REGN) Rises 20.2% Since Previous Earnings Report: Will the Momentum Last?

  • Earnings Performance: Regeneron reported Q3 2025 adjusted EPS of $11.83, exceeding estimates, but down 5% year-over-year. Total revenues grew 1% to $3.7 billion, driven by Eylea HD and Dupixent sales, despite a significant drop in Eylea sales due to competition.

  • Collaboration Revenues: Total collaboration revenues increased by 18.6% year-over-year to $2 billion, with Sanofi's collaboration revenues rising 28% to $1.6 billion, primarily from Dupixent sales, while Bayer's revenues decreased by 12%.

  • Regulatory Updates: The FDA issued a complete response letter for Eylea HD's pre-filled syringe application, while positive opinions were adopted for Dupixent and Libtayo in the EU. Regeneron plans to submit a new application for Eylea HD by January 2026.

  • Market Outlook: Despite a subpar Growth Score of D, Regeneron has seen upward revisions in estimates, with a Zacks Rank of #3 (Hold), indicating an expected in-line return in the coming months.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Viking Therapeutics Inc (VKTX) stock price today?

The current price of VKTX is 38.57 USD — it has increased 8.92 % in the last trading day.

arrow icon

What is Viking Therapeutics Inc (VKTX)'s business?

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.

arrow icon

What is the price predicton of VKTX Stock?

Wall Street analysts forecast VKTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VKTX is 97.27 USD with a low forecast of 70.00 USD and a high forecast of 125.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Viking Therapeutics Inc (VKTX)'s revenue for the last quarter?

Viking Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Viking Therapeutics Inc (VKTX)'s earnings per share (EPS) for the last quarter?

Viking Therapeutics Inc. EPS for the last quarter amounts to -0.81 USD, increased 268.18 % YoY.

arrow icon

What changes have occurred in the market's expectations for Viking Therapeutics Inc (VKTX)'s fundamentals?

The market is revising No Change the revenue expectations for Viking Therapeutics, Inc. (VKTX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 42.96%.
arrow icon

How many employees does Viking Therapeutics Inc (VKTX). have?

Viking Therapeutics Inc (VKTX) has 36 emplpoyees as of December 05 2025.

arrow icon

What is Viking Therapeutics Inc (VKTX) market cap?

Today VKTX has the market capitalization of 4.36B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free